CORD-19:35349bb1fc9290338907b7d7f104c9db3951163b / 0-183 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/35349bb1fc9290338907b7d7f104c9db3951163b","sourcedb":"CORD-19","sourceid":"35349bb1fc9290338907b7d7f104c9db3951163b","text":"ABSTRACTS C01 Pharmacodynamics of Entresto® (Sacubitril/Valsartan) Versus Placebo in Dogs with Preclinical Myxomatous Mitral Valve Disease C02 Trimethylamine-N-Oxide and its Precursor","tracks":[{"project":"CORD-PICO","denotations":[{"id":"p1_all0","span":{"begin":34,"end":81},"obj":"Intervention"},{"id":"p2_i0","span":{"begin":34,"end":66},"obj":"Pharmacological"},{"id":"p2_i1","span":{"begin":74,"end":81},"obj":"Control"}],"attributes":[{"subj":"p1_all0","pred":"source","obj":"CORD-PICO"},{"subj":"p2_i0","pred":"source","obj":"CORD-PICO"},{"subj":"p2_i1","pred":"source","obj":"CORD-PICO"}]},{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1","span":{"begin":118,"end":130},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002135"},{"subj":"T1","pred":"source","obj":"CORD-19-PD-UBERON"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1","span":{"begin":118,"end":138},"obj":"Disease"},{"id":"T20315","span":{"begin":118,"end":138},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"id":"A14104","pred":"mondo_id","subj":"T20315","obj":"http://purl.obolibrary.org/obo/MONDO_0003767"},{"subj":"T1","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T20315","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-PICO","color":"#de93ec","default":true},{"id":"CORD-19-PD-UBERON","color":"#93ecc4"},{"id":"CORD-19-PD-MONDO","color":"#ecaa93"}]}]}}